Ami Fadia
Stock Analyst at Needham
(4.96)
# 111
Out of 4,455 analysts
602
Total ratings
60.1%
Success rate
34.9%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Rated: Buy | $54 → $61 | $55.08 | +10.75% | 16 | Jun 24, 2026 | |
| DFTX Definium Therapeutics | Rated: Buy | $38 → $50 | $44.95 | +11.23% | 9 | Jun 23, 2026 | |
| MPLT MapLight Therapeutics | Rated: Buy | $37 → $42 | $33.28 | +26.20% | 5 | Jun 22, 2026 | |
| BIIB Biogen | Rated: Buy | $255 | $216.03 | +18.04% | 67 | Jun 18, 2026 | |
| NMRA Neumora Therapeutics | Reiterated: Buy | $8 → $5 | $1.64 | +204.88% | 19 | Jun 16, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $537 | $327.79 | +63.82% | 24 | Jun 2, 2026 | |
| IMRX Immuneering | Maintained: Buy | $11 | $4.76 | +131.09% | 31 | Jun 2, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $183 | $182.08 | +0.51% | 32 | Jun 1, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Buy | $15 | $4.10 | +265.85% | 43 | May 22, 2026 | |
| GHRS GH Research | Reiterated: Buy | $32 | $28.22 | +13.39% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 → $15 | $5.29 | +183.55% | 9 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $255 | $230.02 | +10.86% | 68 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $168.52 | +18.68% | 43 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $38 | $25.32 | +50.08% | 37 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 → $45 | $35.47 | +26.87% | 51 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 → $267 | $241.67 | +10.48% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $38.10 | - | 27 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €108.00 | $73.00 | n/a | 8 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $13.87 | n/a | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $7 | $7.69 | n/a | 2 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $15 | $5.55 | n/a | 3 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.33 | n/a | 6 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $63 | $9.95 | n/a | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $5.5 → $6 | $17.23 | n/a | 9 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 | $15.91 | n/a | 9 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $75 | $25.24 | n/a | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.0001 | n/a | 5 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $7 | $0.000001 | n/a | 3 | Dec 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $24 | $0.43 | n/a | 9 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 → $1.5 | $0.05 | n/a | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $9 | $18.15 | n/a | 4 | Aug 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $12 → $14 | $33.21 | n/a | 11 | Aug 6, 2020 |
Alkermes
Jun 24, 2026
Rated: Buy
Price Target: $54 → $61
Current: $55.08
Upside: +10.75%
Definium Therapeutics
Jun 23, 2026
Rated: Buy
Price Target: $38 → $50
Current: $44.95
Upside: +11.23%
MapLight Therapeutics
Jun 22, 2026
Rated: Buy
Price Target: $37 → $42
Current: $33.28
Upside: +26.20%
Biogen
Jun 18, 2026
Rated: Buy
Price Target: $255
Current: $216.03
Upside: +18.04%
Neumora Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $8 → $5
Current: $1.64
Upside: +204.88%
Praxis Precision Medicines
Jun 2, 2026
Maintained: Buy
Price Target: $537
Current: $327.79
Upside: +63.82%
Immuneering
Jun 2, 2026
Maintained: Buy
Price Target: $11
Current: $4.76
Upside: +131.09%
Revolution Medicines
Jun 1, 2026
Maintained: Buy
Price Target: $183
Current: $182.08
Upside: +0.51%
Bicycle Therapeutics
May 22, 2026
Maintained: Buy
Price Target: $15
Current: $4.10
Upside: +265.85%
GH Research
May 15, 2026
Reiterated: Buy
Price Target: $32
Current: $28.22
Upside: +13.39%
May 13, 2026
Rated: Buy
Price Target: $14 → $15
Current: $5.29
Upside: +183.55%
May 11, 2026
Reiterated: Buy
Price Target: $255
Current: $230.02
Upside: +10.86%
May 11, 2026
Reiterated: Buy
Price Target: $200
Current: $168.52
Upside: +18.68%
May 7, 2026
Reiterated: Buy
Price Target: $40 → $38
Current: $25.32
Upside: +50.08%
May 7, 2026
Reiterated: Buy
Price Target: $44 → $45
Current: $35.47
Upside: +26.87%
May 6, 2026
Reiterated: Buy
Price Target: $225 → $267
Current: $241.67
Upside: +10.48%
May 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $38.10
Upside: -
Apr 25, 2025
Reiterated: Buy
Price Target: €108.00
Current: $73.00
Upside: n/a
Dec 14, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $13.87
Upside: n/a
Mar 10, 2021
Reiterated: Buy
Price Target: $10 → $7
Current: $7.69
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $10 → $15
Current: $5.55
Upside: n/a
Mar 2, 2021
Rated: Hold
Price Target: n/a
Current: $16.33
Upside: n/a
Mar 1, 2021
Rated: Buy
Price Target: $63
Current: $9.95
Upside: n/a
Feb 26, 2021
Rated: Hold
Price Target: $5.5 → $6
Current: $17.23
Upside: n/a
Feb 25, 2021
Rated: Buy
Price Target: $16
Current: $15.91
Upside: n/a
Feb 25, 2021
Rated: Hold
Price Target: $75
Current: $25.24
Upside: n/a
Jan 11, 2021
Reiterated: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Dec 30, 2020
Maintained: Buy
Price Target: $10 → $7
Current: $0.000001
Upside: n/a
Dec 2, 2020
Maintained: Buy
Price Target: $19 → $24
Current: $0.43
Upside: n/a
Oct 1, 2020
Maintained: Hold
Price Target: $1 → $1.5
Current: $0.05
Upside: n/a
Aug 14, 2020
Maintained: Buy
Price Target: $8 → $9
Current: $18.15
Upside: n/a
Aug 6, 2020
Maintained: Hold
Price Target: $12 → $14
Current: $33.21
Upside: n/a